The N-terminal sequence of human plasma histidine-rich glycoprotein homologous to antithrombin with high affinity for herapin  by Koide, Takehiko et al.
Volume 141, number 2 FEBS LETTERS May 1982 
THE N-TERMINAL SEQUENCE OF HUMAN PLASMA HISTIDINE-RICH GLYCOPROTEIN 
HOMOLOGOUS TO ANTITHROMBIN WITH HIGH AFFINITY FOR HEPARIN 
Takehiko KOIDE, Shoji ODANI and Teruo ON0 
Department of Biochemistry, Niigata University School of Medicine, 75 7, Asahimachi-dori 1, Niigata-951, Japan 
Received 9 March 1982 
1. Introduction 
Histidine-rich glycoprotein (HRG) is one of the 
plasma glycoproteins whose function is not yet known. 
This protein was first isolated in [ 11; some antifibri- 
nolytic effect of this protein has been suggested [2]. 
Antithrombin is one of the major plasma proteinase 
inhibitors and is known to have high affinity for 
heparin [3]. Lysyl residue(s) of antithrombin is 
reported to be involved in the interaction with heparin 
[3]. However, its location in the amino acid sequence 
is not known. The amino acid sequence of antithrom- 
bin [4] has been shown to be highly homologous to 
or-proteinase inhibitor and ovalbumin, except the 
N-terminal region [.5,6]. Here, we will describe a newly 
isolated plasma protein which has strong heparin- 
binding ability comparable to antithrombin; is possibly 
identical with HRG and show that this protein has a 
homologous N-terminal sequence to that of N-terminal 
region of antithrombin. The results suggest hat the 
putative heparin-binding site of the 2 proteins is 
located at the N-terminal homologous position. 
2. Materials and methods 
2.1. Isolation ofHRG 
A new heparin-binding protein (HBP) was purified 
from human plasma by heparin-agarose affinity 
chromatography, followed by DEAE-Sephadex chro- 
matography (T. K., S. O., T. O., unpublished). The 
heparin-agarose procedure was as in [7]. Fractions 
containing HBP were pooled, dialyzed with 50 mM 
Tris-IO mM Na-citrate-20 mM NaCl (pH 8.0) and 
applied to a column (2.5 X 20 cm) of DEAE- 
Sephadex equilibrated with the same buffer. After 
washing the column with the equilibration buffer, 
HBP was eluted with a linear gradient of NaCl(20- 
520 mM) in the same buffer (total gradient vol., 
600 ml). 
The purified protein gave a single band by SDS- 
polyacrylamide gel electrophoresis. Amino acid anal- 
ysis of this protein showed the unusually high content 
of proline and histidine accounting for >20% of the 
total number of residues, and the amino acid com- 
position was very close to those reported in [l] as 
HRG. High affinity of HRG for heparin was also 
described in [ 11. Identity of this protein as HRG was 
further confirmed by double immunodiffusion method 
using anti-human HRG antiserum prepared as in [ 11. 
2.2. Protein sequence determination 
HRG was reduced and carboxymethylated accord- 
ing to [ 81. The N-terminal amino acid sequence anal- 
ysis of Cm-derivative (7.7 mg) was performed by 
automated Edman degradation [9] in a JEOL JS-47 K 
sequence analyzer using 0.25 M Quadrol buffer and 
double-coupling program at the first step. Phenylthio- 
hydantoin derivatives were semi-quantified by mea- 
suring the absorbance at 269 urn, identified by thin- 
layer chromatography on Kiesel gel F-254 sheets 
(Merck) [ 10,l l] and confirmed by anrino acid anal- 
ysis after back hydrolysis to free amino acids at 
15O’C for 6 h in 6 N HCl containing 0.2% SnCI, [ 121. 
3. Results and discussion 
Twenty-two steps of the Edman degradation of the 
S-carboxymethyl cysteinyl HRG gave the sequence as: 
Val-Ser-Pro-Thr-Asp-Ser-(Ser)-Ala-Val- 
Glu-Pro-Glu-Ala-Glu-Lys-Ala-Leu-Asx- 
Leu-Ile-Asx-Lys. 
The repetitive yield, calculated from the yields of the 
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Fig.1. Comparison of the N-terminal sequence of histidine-rich glycoprotein (HRG) with the sequence of antithrombin [4]. 
Numbering is based on the sequence of each protein. Amino acids enclosed in boxes represent identical residues and functionally 
conserved residues, designated [131 from chemical similarity and accepted point-mutation data. Dash indicates the introduction 
of a gap in the sequence. Serine residue in parentheses i  tentative identification. 
alanine residues in positions g, 13 and 16 was found 
to be 98%. The N-terminal sequence, Val-Ser-Pro, 
is identical to that in [2]. 
Comparison of the N-terminal sequence of HRG 
with the sequence of antithrombin starting with the 
arginine residue-24 (this arginine is also the starting 
residue when compared with cur-proteinase inhibitor 
[6]) reveals that there is a significant degree of 
sequence homology between these 2 plasma proteins 
which are common in the property of high affinity 
for heparin (fig.1). 
HRG, however, showed neither thrombin inhibitory 
activity nor heparin cofactor activity (T. K., unpub- 
lished). These results show that the 2 apparently 
functionally unrelated plasma proteins with heparin- 
binding ability in common have a homologous 
sequence at the N-terminal regions of both proteins. 
Extensive sequence homology between antithrom- 
bin and a,-proteinase inhibitor has been shown all 
through the peptide chains of both proteins except 
the N-terminal regions [6]. According to computer 
analysis of the sequence homology of ovalbumin 
with antithrombin and a,-proteinase inhibitor [S], 
the N-terminal portions of the 2 homologous protein- 
ase inhibitors are not related, and there seem to be 
no proteins, in the Atlas data base [ 131, which are 
homologous to the N-terminal 48 residues of anti- 
thrombin. These facts show that the N-terminal 
sequence of HRG reported here is homologous to 
the very unique portion of antithrombin where even 
aI-proteinase inhibitor reveals no homology. The 
significance of this sequence homology is discussed 
below. 
The binding of heparin to antithrombin molecule 
extremely enhances the protease inhibitory activity 
of the inhibitor [3] and this heparin cofactor activity 
is physiologically very important, for a patient with 
hereditary abnormal antithrombin of the normal pro- 
gressive antithrombin activity and low heparin cofac- 
tor activity suffers from recurrent thrombophlebitis 
[ 141. Although lysyl residue(s) of antithrombin is 
reported to be involved in the interaction with heparin 
[3], its location in the amino acid sequence is not 
known. Thus, the sequence homology at the N-ter- 
minal region of HRG and antithrombin is of interest 
from a heparin-binding point of view. Furthermore, 
it is often observed in plasma proteins that the binding 
site is located at the N-terminal portion, and the bio- 
logically active site at the C-terminal portion: Ca- 
binding site and active serine site of vitamin K-depen- 
dent coagulation factors [ 151, and lysine-binding site 
and active serine site of plasmin [ 161. The reactive 
sites of antithrombin and aI-proteinase inhibitor are 
also located at the C-terminal homologous position 
[6]. From these observations it is likely that the 
heparin-binding sites of antithrombin and HRG are 
also located at the N-terminal portion where the 
sequence of the 2 proteins is homologous. 
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